Hsu Jason, Kaiser Richard S, Sivalingam Arunan, Abraham Prema, Fineman Mitchell S, Samuel Michael A, Vander James F, Regillo Carl D, Ho Allen C
Retina Service, Wills Eye Hospital, Philadelphia, Pennsylvania 19107, USA.
Retina. 2007 Oct;27(8):1013-9. doi: 10.1097/IAE.0b013e318050ca7c.
To describe the effects of intravitreal bevacizumab in eyes with macular edema resulting from central retinal vein occlusions (CRVO).
Retrospective consecutive case series of patients diagnosed with macular edema from CRVO who received intravitreal bevacizumab.
Thirty eyes of 29 patients with an average age of 72 years (range, 54-87 years) had intravitreal bevacizumab injections. Mean follow-up was 18.1 weeks. Initial mean visual acuity was 20/394. At the 1- and 2-month follow-up, mean visual acuity improved to 20/237 (n = 26, P = 0.04) and 20/187 (n = 21, P = 0.008), respectively. At the 3- and 4-month follow-up, visual acuity improved from 20/228 to 20/157 (n = 15, P = 0.05) and from 20/313 to 20/213 (n = 11, P = 0.03), respectively. No significant changes in visual acuity were found after 4 months though the number of patients in this group was small. Duration of treatment effect following an injection appears to be limited to 2 months for most patients. No ocular or systemic adverse reactions were noted.
The visual benefits of intravitreal bevacizumab for macular edema due to CRVO are apparent early but are not sustained without repeated injections. Larger clinical studies with long-term follow-up will be necessary to better elicit the best regimen for this therapy.
描述玻璃体内注射贝伐单抗对视网膜中央静脉阻塞（CRVO）所致黄斑水肿患者眼睛的影响。
对诊断为CRVO所致黄斑水肿并接受玻璃体内注射贝伐单抗的患者进行回顾性连续病例系列研究。
29例平均年龄72岁（范围54 - 87岁）患者的30只眼睛接受了玻璃体内贝伐单抗注射。平均随访时间为18.1周。初始平均视力为20/394。在1个月和2个月随访时，平均视力分别提高到20/237（n = 26，P = 0.04）和20/187（n = 21，P = 0.008）。在3个月和4个月随访时，视力分别从20/228提高到20/157（n = 15，P = 0.05）和从20/313提高到20/213（n = 11，P = 0.03）。4个月后视力无显著变化，尽管该组患者数量较少。对于大多数患者，一次注射后的治疗效果持续时间似乎限于2个月。未观察到眼部或全身不良反应。
玻璃体内注射贝伐单抗对CRVO所致黄斑水肿的视力改善在早期明显，但不重复注射则无法持续。需要进行更大规模的长期随访临床研究，以更好地确定该治疗的最佳方案。
